Disease-free time stratification in locally recurrent head and neck carcinoma after definitive radiotherapy or chemoradiotherapy.
Head and neck neoplasms
Neoplasm recurrence, local
Neoplasms, residual
Neoplasms, second primary
Journal
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
ISSN: 1434-4726
Titre abrégé: Eur Arch Otorhinolaryngol
Pays: Germany
ID NLM: 9002937
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
31
08
2021
accepted:
30
09
2021
pubmed:
15
10
2021
medline:
10
5
2022
entrez:
14
10
2021
Statut:
ppublish
Résumé
There is no standard definition of disease-free interval before local recurrence after treatment in head and neck carcinoma (HNSCC). We evaluated an easy-to-use stratification and its association with survival in a large cohort of patients. We performed a retrospective cohort analysis of prognostic variables in 325 HNSCC patients with a local recurrence after definitive radiotherapy or concurrent chemoradiotherapy. Endpoints were overall survival (OS) and post-recurrence survival (PRS). Variables associated with the survival were the patient age (OS p < 0.0001, PRS p < 0.0001), the initial disease stage (OS p = 0.24, PRS p = 0.0358), localization (OS p = 0.012, PRS p = 0.0002), a complete initial response to treatment (OS p < 0.0001, PRS p = 0.019), synchronous regional or distant metastatic disease (OS p = 0.0094, PRS p < 0.0001), a salvage surgery (OS p < 0.0001, PRS p < 0.0001) and time to recurrence (OS p = 0.0002, PRS p = 0.0029). Time to recurrence could be stratified between specific prognostic time categories that comprised disease persistence, early recurrence (< 12 months), standard recurrence (12 months-5 years) and late recurrence (> 5 years). In HNSCC patients, time to local recurrence is a prognostic variable that can be defined using an easy-to-use stratification.
Identifiants
pubmed: 34648050
doi: 10.1007/s00405-021-07116-6
pii: 10.1007/s00405-021-07116-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3063-3069Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
NIH. Understanding recurrence: what is cancer recurrence? https://www.cancer.org/treatment/survivorship-during-and-after-treatment/understanding-recurrence/what-is-cancer-recurrence.html . Accessed 4 sept 2020
Cohen EE, LaMonte SJ, Erb NL, Beckman KL, Sadeghi N, Hutcheson KA et al (2016) American Cancer Society head and neck cancer survivorship care guideline. CA Cancer J Clin 66:203–239. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approvalcancer-drugs-and-biologics . Accessed 4 sept 2020
doi: 10.3322/caac.21343
FDA (2007) Guidance for industry clinical trial endpoints for the approval of cancer drugs and biologics
Ulm K (2011) Primary endpoints in cancer trials. J Thorac Dis 3:82–83
pubmed: 22263068
pmcid: 3256504
Fiteni F, Westeel V, Pivot X, Borg C, Vernerey D, Bonnetain F (2014) Endpoints in cancer clinical trials. J Visc Surg 151:17–22
doi: 10.1016/j.jviscsurg.2013.10.001
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
doi: 10.1016/j.ejca.2008.10.026
Rohde M, Rosenberg T, Pareek M, Nankivell P, Sharma N, Mehanna H et al (2020) Definition of locally recurrent head and neck squamous cell carcinoma: a systematic review and proposal for the Odense-Birmingham definition. Eur Arch Otorhinolaryngol 277:1593–1599
doi: 10.1007/s00405-020-05953-5
Savina M, Gourgou S, Italiano A, Dinart D, Rondeau V, Penel N et al (2018) Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: a critical review. Crit Rev Oncol Hematol 123:21–41
doi: 10.1016/j.critrevonc.2017.11.014
Hamoir M, Holvoet E, Ambroise J, Lengele B, Schmitz S (2017) Salvage surgery in recurrent head and neck squamous cell carcinoma: oncologic outcome and predictors of disease free survival. Oral Oncol 67:1–9
doi: 10.1016/j.oraloncology.2017.01.008
Chang JH, Wu CC, Yuan KS, Wu ATH, Wu SY (2017) Locoregionally recurrent head and neck squamous cell carcinoma: incidence, survival, prognostic factors, and treatment outcomes. Oncotarget 8:55600–55612
doi: 10.18632/oncotarget.16340
Tan HK, Giger R, Auperin A, Bourhis J, Janot F, Temam S (2010) Salvage surgery after concomitant chemoradiation in head and neck squamous cell carcinomas - stratification for postsalvage survival. Head Neck 32:139–147
doi: 10.1002/hed.21368
Rasmussen JH, Gronhoj C, Hakansson K, Friborg J, Andersen E, Lelkaitis G et al (2019) Risk profiling based on p16 and HPV DNA more accurately predicts location of disease relapse in patients with oropharyngeal squamous cell carcinoma. Ann Oncol 30:629–636
doi: 10.1093/annonc/mdz010
Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091–2098
doi: 10.1056/NEJMoa031317
Sandulache VC, Vandelaar LJ, Skinner HD, Cata J, Hutcheson K, Fuller CD et al (2016) Salvage total laryngectomy after external-beam radiotherapy: a 20-year experience. Head Neck 38(Suppl 1):E1962–E1968
doi: 10.1002/hed.24355
Gorphe P, Tao Y, Blanchard P, Even C, Moya-Plana A, Mirghani H et al (2017) Relationship between the time to locoregional recurrence and survival in laryngeal squamous-cell carcinoma. Eur Arch Otorhinolaryngol 274:2267–2271
doi: 10.1007/s00405-017-4473-3
Caula A, Boukhris M, Guerlain J, Tao Y, Breuskin I, Mirghani H et al (2019) Correlation between the duration of locoregional control and survival in T1–T2 oropharyngeal cancer patients. Eur Arch Otorhinolaryngol 276:1161–1166
doi: 10.1007/s00405-019-05293-z
Zafereo ME, Hanasono MM, Rosenthal DI, Sturgis EM, Lewin JS, Roberts DB et al (2009) The role of salvage surgery in patients with recurrent squamous cell carcinoma of the oropharynx. Cancer 115:5723–5733
doi: 10.1002/cncr.24595
NIH. NCI dictionaries: relapse-free survival. Accessed 4 sept 2020
Kemp R, Prasad V (2017) Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? BMC Med 15:134
doi: 10.1186/s12916-017-0902-9